MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

MediciNova Inc

Closed

SectorHealthcare

1.31 -6.43

Overview

Share price change

24h

Current

Min

1.27

Max

1.39

Key metrics

By Trading Economics

Income

38K

-2.8M

EPS

-0.06

Employees

13

EBITDA

125K

-3.2M

Dividends

By Dow Jones

Next Earnings

7 maj 2025

Market Stats

By TradingEconomics

Market Cap

-15M

72M

Previous open

7.74

Previous close

1.31

News Sentiment

By Acuity

42%

58%

153 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

MediciNova Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 kwi 2025, 23:55 UTC

Hot Stocks

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 kwi 2025, 22:50 UTC

Major Market Movers

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 kwi 2025, 21:08 UTC

Earnings

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 kwi 2025, 21:00 UTC

Earnings

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 kwi 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 kwi 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 kwi 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 kwi 2025, 23:44 UTC

Top News

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 kwi 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 kwi 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 kwi 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 kwi 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 kwi 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 kwi 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 kwi 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 kwi 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 kwi 2025, 22:43 UTC

Top News
Acquisitions, Mergers, Takeovers

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 kwi 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 kwi 2025, 21:48 UTC

Top News

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 kwi 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 kwi 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 kwi 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 kwi 2025, 21:04 UTC

Top News

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 kwi 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 kwi 2025, 20:53 UTC

Earnings

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 kwi 2025, 20:52 UTC

Earnings

Kaiser Aluminum Changes Inventory Acctg Methodology

Peer Comparison

Price change

MediciNova Inc Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

N/A / 1.4505Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

153 / 386 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.